Menu
Search
|

Menu

Close
X

Accelerate Diagnostics Inc AXDX.OQ (NASDAQ Stock Exchange Capital Market)

22.35 USD
+0.75 (+3.47%)
As of 4:00 PM EDT
chart
Previous Close 21.60
Open 21.55
Volume 56,438
3m Avg Volume 56,576
Today’s High 22.65
Today’s Low 21.55
52 Week High 30.30
52 Week Low 16.85
Shares Outstanding (mil) 53.98
Market Capitalization (mil) 1,193.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.20 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
4
FY16
0
FY15
0
EPS (USD)
FY18
-0.374
FY17
-1.183
FY16
-1.294
FY15
-1.010
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.86
Price to Sales (TTM)
vs sector
268.27
8.16
Price to Book (MRQ)
vs sector
10.94
4.20
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
93.13
17.38
LT Debt to Equity (MRQ)
vs sector
93.13
13.24
Return on Investment (TTM)
vs sector
-51.41
13.13
Return on Equity (TTM)
vs sector
-80.45
15.07

EXECUTIVE LEADERSHIP

John Patience
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Lawrence Mehren
President, Chief Executive Officer, Director, Since 2012
Salary: $360,577.00
Bonus: --
Steve Reichling
Chief Financial Officer, Since 2012
Salary: $230,385.00
Bonus: --
Joan Martin
Executive Vice President & Head of Europe, Middle East, and Africa, Since 2017
Salary: $359,395.00
Bonus: --
Ron Price
Senior Vice President and Head of Commercial Operations, Americas, Since 2017
Salary: $315,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

3950 S. Country Club Road #470
Building 3-307
TUCSON   AZ   85714-2240

Phone: +1303.8638088

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

SPONSORED STORIES